FungiScope

Mission Statement

FungiScope® – A Global Registry for Invasive Fungal Infections was launched in 2003 with the aim to improve patient care by collecting data on the epidemiology, pathogen biology and clinical course of invasive fungal infections all over the world. Our anonymous and retrospective case collection allows us to gain a deeper insight into the current global management of such cases and can assist in the development and implementation of more effective prevention and treatment strategies or adherence to international management guidelines.

To overcome the difficulties in treatment of invasive candidiasis and candidemia infections due to increasing resistance, the FungiScope Candida Campaign was initiated in 2024 by Prof. Dr. Oliver Cornely, MD and Dr. Danila Seidel, PhD as a sub-project of FungiScope® – A Global Invasive Fungal Infection Registry. Our aim is to collect 3,000 cases of invasive Candida infections in Europe, the USA, Brazil and other countries in our registry by the end of 2026 to investigate the current epidemiology and to describe diagnostic and treatment strategies of these infections. We offer joint publications with authorships for each set of 10 consecutive cases per site per year and additional country-specific publications led by the respective country coordinators.

For participation, please contact: fungiscope@uk-koeln.de

Achievements of the working group in 2023

• In 2023, 786 new cases of invasive fungal infections were included in the registry, most reported from Germany, the United States, Spain, India, China, Japan, France, Russia, Italy, and Australia. These included cases with mixed fungal infections and aspergillosis with galactomannan follow up during treatment.
• Several publications on the epidemiology and treatment of emerging IFI, e.g., infections caused by invasive candidemia and aspergillosis, COVID-19-associated mucormycosis and infections of Pneumocystis jirovecii pneumonia.
• New Candida EQUAL Score App to quantify guideline adherence released.

Upcoming events planned for 2024-2025

Publications arising from the Working Group

• Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. Hoenigl M, Salmanton-García J, Egger M, Gangneux J-P, Bicanic T, Arikan-Akdagli S, Alastruey-Izquierdo A, Klimko N, Barac A, Özenci V, Meijer EFJ, Khanna N, Bassetti M, Rautemaa-Richardson R, Lagrou K, Adam K-M, Akalin E H, Akova M, Arsenijevic VA, Aujayeb A, Blennow O, Bretagne S, Danion F, Denis B, de Jonge NA, Desoubeaux G, Drgona L, Erben N, Gori A, Rodríguez JG, Garcia-Vidal C, Giacobbe DR, Goodman AL, Hamal P, Hammarström H, Toscano C, Lanternier F, Lass-Flörl C, Lockhart DEA, Longval T, Loughlin L, Matos T, Mikulska M, Narayanan M, Martín-Pérez S, Prattes J, Rogers B, Rahimli L, Ruiz M, Roilides E, Samarkos M, Scharmann U, Sili U, Sipahi OR, Sivakova A, Steinmann J, Trauth J, Turhan O, Van Praet J, Vena A, White PL, Willinger B, Tortorano AM, Arendrup MC, Koehler P, Cornely OA, on behalf of the ECMM Candida III Study Group. Lancet Infect Dis. 2023;23(6):751-761. doi:10.1016/S1473-3099(22)00872-6.
• Diagnosis and Treatment of Invasive Aspergillosis Caused by Non-fumigatus Aspergillus spp. Stemler J, Többen C, Lass-Flörl C, Steinmann J, Ackermann K, Rath P-M, Simon M, Cornely OA, Koehler P. J. Fungi 2023, 9(4), 500. doi: 10.3390/jof9040500.
• COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases. Özbek L, Topçu U, Manay M, Esen BH, Bektas SN, Aydın S, Özdemir B, Khostelidi SN, Klimko N, Cornely O, Zakhour J, Kanj SS, Seidel D, Hoenigl M, Ergönül Ö. Clin Microbiol Infect. 2023;29(6):722-731. doi: 10.1016/j.cmi.2023.03.008.
• Which trial do we need? Combination treatment of Pneumocystis jirovecii pneumonia in non-HIV infected patients. Koehler P, Prattes J, Simon M, Haensel L, Hellmich M, Cornely OA. Clin Microbiol Infect. 2023;S1198-743X(23)00208-2. doi: 10.1016/j.cmi.2023.05.004. Online ahead of print.
• How to diagnose and treat a patient without human immunodeficiency virus infection having Pneumocystis jirovecii pneumonia? Hänsel L, Schumacher J, Denis B, Hamane S, Cornely OA, Koehler P. Clin Microbiol Infect. 2023;S1198-743X(23)00186-6.
• Antifungal prophylaxis and pre-emptive therapy: When and how? Sprute R, Nacov JA, Neofytos D, Oliverio M, Prattes J, Reinhold I, Cornely OA, Stemler J. Mol Aspects Med. 2023;92:101190. doi: 10.1016/j.mam.2023.101190.
• The silent flucytosine shortage in Europe – not a distant problem. Sprute R, Duda S, Liekweg A, Simon M, Cornely OA. Lancet Reg Health Eur. 2023;30: 100658. doi: 10.1016/j.lanepe.2023.100658.
• Characterization of Treatment Response Outcomes in Chronic Pulmonary Aspergillosis: CPAnet Definitions Versus the Existing Criteria. Sehgal IS, Arora K, Cornely OA, Salzer HJF, Dhooria S, Prasad KT, Garg M, Rudramurthy SM, Muthu V, Aggarwal AN, Chakrabarti A, Agarwal R. Mycopathologia. 2023;721-730.
  doi: 10.1007/s11046-023-00751-z.
• The Argentinian landscape of mycological diagnostic capacity and treatment accessibility. Riera F, Caeiro JP, Cornely OA, Salmanton-García J. Med Mycol. 2023;myad058. doi: 10.1093/mmy/myad058.
• Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis. Jeck J, Jakobs F, Kurte MS, Cornely OA, Kron F. JAC Antimicrob Resist. 2023;5:dlad079. doi: 10.1093/jacamr/dlad079.
• How to diagnose and treat a patient without human immunodeficiency virus infection having Pneumocystis jirovecii pneumonia? Hänsel L, Schumacher J, Denis B, Hamane S, Cornely OA, Koehler P. Clin Microbiol Infect. 2023;29(8):1015-1023. doi: 10.1016/j.cmi.2023.04.015.
• Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Stemler J, Mellinghoff SC, Khodamoradi Y, Sprute R, Classen AY, Zapke SE, Hoenigl M, Krause R, Schmidt-Hieber M, Heinz WJ, Klein M, Koehler P, Liss B, Koldehoff M, Buhl C, Penack O, Maschmeyer G, Schalk E, Lass-Flörl C, Karthaus M, Ruhnke M, Cornely OA, Teschner D. J Antimicrob Chemother. 2023;78(8):1813-1826. doi: 10.1093/jac/dkad143.
• Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study. Egger M, Salmanton-Garcia J, Barac A, Gangneux JP, Guegan H, Arsic-Arsenijevic V, Matos T, Tomazin R, Klimko N, Bassetti M, Hammarström H, Meijer EFJ, Meis JF, Prattes J, Krause R, Sipahi OR, Scharmann U, White PL, Desoubeaux G, García-Rodríguez J, Garcia-Vidal C, Martín-Pérez S, Ruiz M, Tumbarello M, Talento AF, Rogers B, Lagrou K, van Praet J, Arikan-Akdagli S, Arendrup MC, Koehler P, Cornely OA, Hoenigl M, on behalf of the ECMM Candida III Study Group. Mycopathologia. 2023;188(6):983-994. doi: 10.1007/s11046-023-00776-4.
• The Austrian landscape of diagnostic capacity and access to treatment for invasive fungal infections. Salmanton-García J, Hoenigl M, Salzer HJF, Lackner M, Prattes J, Dichtl K, Winkler-Zamani M, Krause R, Stemler J, Lass-Flörl C, Cornely OC, Willinger B. Mycoses. 2023;66(12):1056-1063. doi: 10.1111/myc.13650.
• European candidaemia is characterised by notable differential epidemiology and susceptibility pattern; Results from the ECMM Candida III study. Arendrup MC, Arikan-Akdagli S, Jørgensen KM, Barac A, Steinmann J, Toscano C, Arsenijevic VA, Sartor A, Lass-Flörl C, Hamprecht A, Matos T, Rogers BRS, Quiles I, Buil J, Özenci V, Krause R, Bassetti M, Loughlin L, Denis B, Grancini A, White PL, Lagrou K, Willinger B, Rautemaa-Richardson R, Hamal P, Ener B, Unalan-Altintop T, Evren E, Hilmioglu-Polat S, Oz Y, Ozyurt OK, Aydin F, Růžička F, Meijer EFJ, Gangneux JP, Lockhart DEA, Khanna N, Logan C, Scharmann U, Desoubeaux G, Roilides E, Talento AF, van Dijk K, Koehler P, Salmanton-García J, Cornely OA, Hoenigl M. J Infect. 2023;S0163-4453(23)00451-6. doi: 10.1016/j.jinf.2023.08.001.
• Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG. Giacobbe DR, Dettori S, Di Pilato V, Asperges E, Ball L, Berti E, Blennow O, Bruzzone B, Calvet L, Marzani FC, Casabella A, Choudaly S, Dartevel A, De Pascale G, Di Meco G, Fallon M, Galerneau LM, Gallego M, Giacomini M, González Sáez A, Hänsel L, Icardi G, Koehler P, Lagrou K, Lahmer T, White PL, Magnasco L, Marchese A, Marelli C, Marín‑Arriaza M, Martin‑Loeches I, Mekontso‑Dessap A, Mikulska M, Mularoni A, Nordlander A, Poissy J, Russelli G, Signori A, Tascini C, Vaconsin LM, Vargas J, Vena A, Wauters J, Pelosi P, Timsit JF and Bassetti M on behalf of JIR-ICU investigators (collaborators) the Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Diseases (ESGCIP), and the Fungal Infection Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EFISG). Crit Care. 2023;27(1):323. doi: 10.1186/s13054-023-04608-1.
• Laboratory and clinical management capacity for invasive fungal infections: the Italian landscape. Vena A, Bassetti M, Mezzogori L, Marchesi F, Hoenigl M, Giacobbe DR, Corcione S, Bartoletti M, Stemler J, Pagano L, Cornely OA, Salmanton-Garcia J. Infection. 2024;52(1):197-208. doi: 10.1007/s15010-023-02084-x.
• Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. Cornely OA, Ostermann H, Koehler P, Teschner D, Limburg E, Kramer WG, Barbat SH, Tawadrous M, Hodges MR. J Antimicrob Chemother. 2023;dkad269. doi: 10.1093/jac/dkad269.
• Which trial do we need? Combination treatment of Pneumocystis jirovecii pneumonia in non-HIV infected patients. Koehler P, Prattes J, Simon M, Haensel L, Hellmich M, Cornely OA. Clin Microbiol Infect. 2023;29(10):1225-1228. doi: 10.1016/j.cmi.2023.05.004.
• Invasive Mykosen in Onkologie und Hämatologie: Überlebenschance häufig nur bei sofortigem Handeln. Stemler J, Bekaan N, Nacov J, Cornely OA. Dtsch Arztebl 2023; 120(42):16. doi: 10.3238/PersOnko.2023.10.20.03.
• A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC. de Hoog S, Walsh TJ, Ahmed SA, Alastruey-Izquierdo A, Alexander BD, Arendrup MC, Babady E, Bai F-Y, Balada-Llasat J-M,  Borman A, Chowdhary A, Clark A, Colgrove RC, Cornely OA, Dingle TC, Dufresne PJ, Fuller J, Gangneux J-P, Gibas C, Glasgow H, Gräser Y, Guillot J, Groll AH, Haase G, Hanson K, Harrington A,  Hawksworth DL, Hayden RT, Hoenigl M, Hubka V, Johnson K, Kus JV, Li R, Meis JF, Lackner M, Lanternier F, Leal Jr. SM, Lee F, Lockhart SR, Luethy P, Martin I, Kwon-Chung KJ, Meyer W,  Nguyen MH, Ostrosky-Zeichner L, Palavecino E, Pancholi P, Pappas PG, Procop GW, Redhead SA, Rhoads DD, Riedel S, Stevens B, Sullivan KO, Vergidis P, Roilides E, Seyedmousavi A, Tao L, Vicente VA, Vitale RG, Wang Q-M, Wengenack NL, Westblade L, Wiederhold N, White L, Wojewoda CM, Zhang SX. J Clin Microbiol. 2023:e0087323. doi: 10.1128/jcm.00873-23.
• Questioning the 14-day dogma in candidemia treatment duration. Salmanton-García J, Reinhold I, Prattes J, Bekaan N, Koehler P, Cornely OA. Mycoses. 2024;67(1):e13672. doi: 10.1111/myc.13672.
• Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. Thompson III GR, Soriano A, Honore PM, Bassetti M, Cornely OA, Kollef M, Kullberg BJ, Pullman J, Hites M, Fortún J, Horcajada JP, Kotanidou A, Das AF, Sandison T, Aram JA, Vazquez JA, Pappas PG. The Lancet. 2024;24(3):319-328. doi: 10.1016/S1473-3099(23)00551-0.
• Social determinants of health as drivers of fungal disease. Jenks JD, Prattes J, Wurster S, Sprute R, Seidel D, Oliverio M, Egger M, Del Rio C, Sati H, Cornely OA, Thompson GR, Kontoyiannis DP, Hoenigl M. EClinicalMedicine. 2023;66:102325. doi: 10.1016/j.eclinm.2023.102325.
• Fatal pulmonary hemorrhage, pneumothorax and skin necrosis caused by IRIS to an Aspergillus flavus infection in a young patient with metamizole associated agranulocytosis. Banz M, Stallmach A, Gaßler N, Schulze PC, Fritzenwanger M, Cornely O, Kurzai O, Pletz MW. Infection. 2024;52(2):685-690.
  doi: 10.1007/s15010-023-02149-x.
• Unveiling the Hungarian landscape of laboratory and clinical management capacities for invasive fungal infections: navigating the frontlines against fungal menaces. Renátó Kovács, László Majoros, Jannik Stemler, Oliver Andreas Cornely and Jon Salmanton-García. Ther Adv Infect Dis. 2023;10:20499361231219315. doi: 10.1177/20499361231219315.
• The Nairobi Declaration 2023: A Commitment to Address Deadly Yet Neglected Fungal Diseases in Africa. Osaigbovo I, Govender NP, Jordan AM, Bongomin F, Meya DB, Kanyua A, Mashedi OM, Koffi D, Loyse A, Sturny-Leclère A, Gangneux J-P, Denning DW, Chiller T, Cornely O, Oladele RO. Med Mycol. 2024;62(1):myad141.doi: 10.1093/mmy/myad141.

Funding provided by ISHAM in the past 3 years

None.